A pharmaceutical factory in Grangemouth is set to expand following a £45m investment, which is expected to create up to 50 new jobs.
India-based Piramal Pharma Solutions is adding two new ADC (Antibody-Drug Conjugate) manufacturing suites to its Grangemouth site, which will add to the existing three.
The move, which will create up to 50 new jobs, is expected to improve the development of clinical products rapidly, and to support cancer drug trials.
The move will bring the total number of employees at the site to more than 250.
Scottish Enterprise, who are investing £2.4m into the expansion, have said it is “tremendous news” for Scotland’s life sciences sector.
Scottish Enterprise chief executive Adrian Gillespie said: “Piramal’s investment is tremendous news for Scotland’s life sciences sector, one of the largest life sciences clusters in Europe, and is creating new, high-quality jobs that are crucial to our economic recovery.
“With Scottish Enterprise support, the company’s Grangemouth site expansion proposals will deliver more R&D and production capacity for the development, scale-up and commercial manufacture of drugs in the global fight against cancer.”
Piramal Pharma chief executive Peter DeYoung said: “This new development will more than double our ADC production capacity, strengthening our ability to service customers throughout the entire drug lifecycle.”